The global proteinuria treatment market, valued at USD 1.9 billion in 2022, is poised for significant growth, with a projected compound annual growth rate (CAGR) of 8% over the next decade. By 2032, the market is expected to reach a valuation of USD 4.10 billion, driven by the increasing prevalence of chronic kidney disease (CKD) and the growing clinical advancements in proteinuria treatment.
Proteinuria, characterized by the presence of excess protein in urine, is commonly associated with CKD, a condition affecting millions worldwide. According to the Centers for Disease Control and Prevention (CDC), nearly one in seven adults in the U.S.—over 37 million people—suffer from CKD. The prevalence is notably higher among individuals aged 65 and above, emphasizing the growing demand for effective proteinuria treatments. As CKD remains a leading cause of kidney failure, the rising number of cases is expected to fuel market growth in the coming years.
Clinical innovation in kidney treatments is also playing a key role in market expansion. Notably, in June 2021, Novartis unveiled promising Phase II data for ‘iptacopan,’ an investigational drug that showed a substantial reduction in proteinuria, a critical marker of kidney dysfunction. Iptacopan, a targeted factor B inhibitor, demonstrated a stabilizing effect on kidney function in patients with IgA nephropathy, a kidney disorder linked to proteinuria. The success of such clinical trials signals a positive outlook for the development of novel proteinuria treatments.
Further propelling the market’s growth are strategic mergers, acquisitions, and licensing agreements. In January 2020, Chinook Therapeutics Inc. entered into an exclusive global licensing agreement with AbbVie for ‘atrasentan,’ a promising endothelin receptor antagonist. Atrasentan is being developed to treat primary glomerular diseases characterized by proteinuria, positioning it as a potential breakthrough in addressing this prevalent health concern.
As the market for proteinuria treatments continues to evolve, stakeholders are optimistic about the opportunities for growth driven by rising CKD rates, ongoing clinical advancements, and strategic partnerships that aim to bring innovative treatments to market. With a focus on improving kidney health and minimizing the risk of kidney failure, the global proteinuria treatment market is set to witness robust expansion in the years ahead.
Surge in Market Demand: Explore Comprehensive Trends and Analysis in Our Full Report!
The proteinuria treatment market is influenced by several key drivers and restraints that impact its growth trajectory. Below are the primary drivers and restraints in this market:
Drivers:
- Increasing Prevalence of Kidney Diseases:
- The rising incidence of chronic kidney diseases (CKD), diabetes, hypertension, and other conditions that cause proteinuria is a major driver. Proteinuria is often a key marker for kidney damage, and the need for effective treatments is increasing as these diseases become more common worldwide.
- Advances in Medical Research:
- Ongoing advancements in research are leading to the development of novel therapies for managing proteinuria, including biologics, immunosuppressive agents, and targeted therapies. This innovation is fueling market growth by providing more effective treatment options.
- Rising Awareness and Early Diagnosis:
- Improved awareness of proteinuria, particularly as a symptom of kidney disease, is leading to earlier diagnoses. As a result, there is an increasing demand for proteinuria treatments. Regular screening, especially in high-risk populations, contributes to early detection and treatment, further driving market growth.
- Growing Geriatric Population:
- The aging population is more susceptible to kidney diseases and conditions like hypertension and diabetes, which can lead to proteinuria. As the global geriatric population increases, so does the demand for treatments to manage proteinuria and prevent kidney damage.
- Government and Healthcare Initiatives:
- Governments and healthcare organizations are focusing on kidney health and disease prevention, with initiatives aimed at reducing the burden of kidney-related diseases. These efforts contribute to increased diagnosis rates and, in turn, demand for effective treatment solutions for proteinuria.
Restraints:
- High Treatment Costs:
- The cost of advanced treatments, including biologics and immunosuppressive therapies, can be prohibitive. This is particularly challenging for patients in low-income regions or for those without adequate insurance coverage, limiting market growth in certain demographics.
- Side Effects of Current Treatments:
- Some of the current treatments for proteinuria, particularly immunosuppressive drugs, can have significant side effects, including increased susceptibility to infections, organ toxicity, and other complications. The side effect profile of these treatments may limit their adoption or long-term use, especially in older patients or those with comorbidities.
- Regulatory Hurdles:
- Regulatory approval for new proteinuria treatments can be a lengthy and complex process, especially for biologics and novel therapies. This may delay the availability of innovative treatments, restricting market expansion.
- Lack of Awareness in Low-Income Regions:
- In regions where awareness of kidney diseases and proteinuria is low, the lack of early diagnosis and treatment may hinder market growth. Limited healthcare infrastructure and access to diagnostic facilities can also contribute to underdiagnosis and undertreatment of proteinuria.
- Competition from Generic Drugs:
- Many of the existing treatments for proteinuria are available as generics, which are more affordable but may offer limited efficacy compared to newer branded therapies. This may slow the uptake of more advanced treatments, particularly in cost-sensitive markets.
In summary, the proteinuria treatment market is poised for growth due to the increasing prevalence of kidney diseases, advances in medical research, and growing awareness. However, challenges such as high treatment costs, side effects of existing therapies, and regulatory hurdles may restrain market development.
Proteinuria Treatment Market: Key Players
Some of the key players contributing to the global proteinuria treatment market includes Eli Lilly And Company, Bristol-Myers Squibb, Merck & Co, Inc., AstraZeneca Plc., Reddys Lab, and Novartis AG.
Proteinuria Treatment Market: Segmentation
Proteinuria treatment market can be segmented on the basis of drug type, distribution channel and geography.
Based on drug type, proteinuria treatment market can be segmented as follows:
- ACE inhibitors (angiotensin-converting enzyme inhibitors)
- ARBs (angiotensin receptor blockers)
- DPP (dipeptidyl peptidase) IV inhibitors
Based on distribution channel, proteinuria treatment market can be segmented as follows:
- Hospitals including hospital pharmacies
- Clinics
- Retail Pharmacies
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
